Onco Wiki / Biomarqueur

Statut HTLV-1 (anticorps anti-HTLV1 + confirmation)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDBIO-HTLV-1
TypeBiomarqueur
Alias
HTLV-1 sérologieHTLV-IStatut du virus T lymphotrope humain de type 1anti-HTLV-1Статус HTLV-1 (антитіла + підтвердження)
Étatreviewed 2026-04-26 | pending_clinical_signoff
MaladiesDIS-ATLL
SourcesSRC-NCCN-BCELL-2025

Données biomarqueurs

Type de biomarqueurviral_serology
Mesure
MéthodeAnti-HTLV-1 antibody screening (EIA or particle agglutination); reactive → confirmatory Western blot or line immunoassay to distinguish HTLV-1 from HTLV-2 and rule out indeterminate patterns. HTLV-1 proviral load (qPCR on PBMCs) is informative but not standardized — high proviral load (>4% of PBMCs) correlates with ATLL transformation risk in carriers but is NOT a treatment-decision biomarker in active ATLL.
Unitéscategorical: HTLV-1 seropositive (carrier vs ATLL clinical) | seronegative
Biomarqueurs connexesBIO-HIV-STATUS

Notes

HTLV-1 etiology is the defining feature of Adult T-Cell Leukemia/Lymphoma (ATLL); WHO classification requires HTLV-1 seropositivity + clonal HTLV-1 integration on Southern blot (or qPCR equivalent) for diagnosis. Geographic context matters for Ukraine: HTLV-1 prevalence is low (<0.1% in non-endemic Europe); endemic areas are Japan, Caribbean, parts of Sub-Saharan Africa, South America. ATLL diagnosis in a Ukrainian patient should prompt travel / heritage history; rare but real. Currently consumed by: ALGO-ATLL-1L (etiology rail — HTLV-1+ is necessary for ATLL classification; subtype determined by clinical features per Shimoyama). Quantitative proviral load monitoring flagged as a future Monitoring entity for asymptomatic carriers who are not currently candidates for treatment. reviewer_signoffs: 0 # STUB — pending two Clinical Co-Lead approvals

Utilisé par

Algorithmes

Indication

Questionnaires